TheRyte (UK)

TheRyte is a Liverpool-based bioscience company founded in 2001 which has developed a compound with proven biological activity against a broad-spectrum anticancer target. This development is based on a completely new and breakthrough understanding of how cancer works discovered by Professor Hilmar Warenius, a clinical oncologist at the University of Liverpool, and is highly cancer cell specific without any observed adverse effects on normal cells. For more information, visit


Case Studies